Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Aromatase inhibitors and calcium absorption in early stage breast cancer.

Tevaarwerk A, Burkard ME, Wisinski KB, Shafer MM, Davis LA, Gogineni J, Crone E, Hansen KE.

Breast Cancer Res Treat. 2012 Jul;134(1):245-51. doi: 10.1007/s10549-012-1982-z. Epub 2012 Feb 18.

2.

Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer.

Folkerd EJ, Dixon JM, Renshaw L, A'Hern RP, Dowsett M.

J Clin Oncol. 2012 Aug 20;30(24):2977-80. doi: 10.1200/JCO.2012.42.0273. Epub 2012 Jul 16.

PMID:
22802308
3.

Expression of estrogen-related gene markers in breast cancer tissue predicts aromatase inhibitor responsiveness.

Moy I, Lin Z, Rademaker AW, Reierstad S, Khan SA, Bulun SE.

PLoS One. 2013 Nov 6;8(11):e77543. doi: 10.1371/journal.pone.0077543. eCollection 2013.

4.

Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial.

Goss PE, Hershman DL, Cheung AM, Ingle JN, Khosla S, Stearns V, Chalchal H, Rowland K, Muss HB, Linden HM, Scher J, Pritchard KI, Elliott CR, Badovinac-Crnjevic T, St Louis J, Chapman JA, Shepherd LE.

Lancet Oncol. 2014 Apr;15(4):474-82. doi: 10.1016/S1470-2045(14)70035-X. Epub 2014 Mar 11.

5.

Need for estradiol assays with a lower functional sensitivity in clinical studies examining postmenopausal women treated with aromatase inhibitors.

Pauwels S, Lintermans A, Neven P, Verhaeghe J, Jans I, Billen J, Vanderschueren D, Vermeersch P.

J Clin Oncol. 2013 Feb 1;31(4):509. doi: 10.1200/JCO.2012.46.2622. Epub 2012 Dec 26. No abstract available.

PMID:
23270000
6.

Impact of BMI on serum estradiol and bone turnover markers in postmenopausal women with hormone-sensitive early breast cancer treated with anastrozole.

Kyvernitakis I, Knöll D, Struck M, Hars O, Bauer T, Hadji P.

J Cancer Res Clin Oncol. 2014 Jan;140(1):159-66. doi: 10.1007/s00432-013-1557-3. Epub 2013 Nov 29.

PMID:
24292402
7.

Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover.

Oesterreich S, Henry NL, Kidwell KM, Van Poznak CH, Skaar TC, Dantzer J, Li L, Hangartner TN, Peacock M, Nguyen AT, Rae JM, Desta Z, Philips S, Storniolo AM, Stearns V, Hayes DF, Flockhart DA.

Breast Cancer Res Treat. 2015 Nov;154(2):263-73. doi: 10.1007/s10549-015-3608-8. Epub 2015 Nov 4.

8.

A prospective, multicenter, controlled, observational study to evaluate the efficacy of a patient support program in improving patients' persistence to adjuvant aromatase inhibitor medication for postmenopausal, early stage breast cancer.

Yu KD, Zhou Y, Liu GY, Li B, He PQ, Zhang HW, Lou LH, Wang XJ, Wang S, Tang JH, Liu YH, Wang X, Jiang ZF, Ma LW, Gu L, Cao MZ, Zhang QY, Wang SM, Su FX, Zheng H, Li HY, Tang LL, Sun SR, Liu JP, Shao ZM, Shen ZZ.

Breast Cancer Res Treat. 2012 Jul;134(1):307-13. doi: 10.1007/s10549-012-2059-8. Epub 2012 Apr 12.

PMID:
22527106
9.

Aromatase inhibition in obese women: how much is enough?

Ligibel JA, Winer EP.

J Clin Oncol. 2012 Aug 20;30(24):2940-2. doi: 10.1200/JCO.2012.43.7244. Epub 2012 Jul 16. No abstract available.

PMID:
22802318
10.

Hormonal and dietary influences on true fractional calcium absorption in women: role of obesity.

Shapses SA, Sukumar D, Schneider SH, Schlussel Y, Brolin RE, Taich L.

Osteoporos Int. 2012 Nov;23(11):2607-14. doi: 10.1007/s00198-012-1901-5. Epub 2012 Jan 27.

11.

Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.

Carpenter R.

Eur J Surg Oncol. 2008 Jul;34(7):746-55. doi: 10.1016/j.ejso.2008.01.011. Epub 2008 Mar 4. Review.

PMID:
18296017
12.

Update on the use of letrozole in breast cancer.

Wu M, Goss PE.

Expert Opin Pharmacother. 2007 Oct;8(14):2329-45. Review.

PMID:
17927487
13.

ERBB2 status and outcome of endocrine treatment.

Miller WR.

Lancet Oncol. 2008 Jan;9(1):4-5. doi: 10.1016/S1470-2045(07)70389-3. No abstract available.

PMID:
18177812
14.

Serum estradiol should be monitored not only during the peri-menopausal period but also the post-menopausal period at the time of aromatase inhibitor administration.

Nagao T, Kira M, Takahashi M, Honda J, Hirose T, Tangoku A, Zembutsu H, Nakamura Y, Sasa M.

World J Surg Oncol. 2009 Nov 12;7:88. doi: 10.1186/1477-7819-7-88.

15.

Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer.

Khan QJ, Reddy PS, Kimler BF, Sharma P, Baxa SE, O'Dea AP, Klemp JR, Fabian CJ.

Breast Cancer Res Treat. 2010 Jan;119(1):111-8. doi: 10.1007/s10549-009-0495-x. Epub 2009 Aug 5.

16.

Should all postmenopausal patients with hormone receptor-positive breast cancer receive initial therapy with aromatase inhibitors?

Aapro M, van de Velde CJ, Markopoulos C, Bartlett JM, Putter H, Coleman RE.

Breast. 2013 Aug;22(4):488-94. doi: 10.1016/j.breast.2013.01.007. Epub 2013 Feb 27.

PMID:
23454040
19.

Effect of anastrozole and tamoxifen on lipid metabolism in Japanese postmenopausal women with early breast cancer.

Sawada S, Sato K, Kusuhara M, Ayaori M, Yonemura A, Tamaki K, Hiraide H, Mochizuki H, Ohsuzu F.

Acta Oncol. 2005;44(2):134-41.

PMID:
15788292
20.

Anti-tumor effects of letrozole.

Miller WR, Anderson TJ, Dixon JM.

Cancer Invest. 2002;20 Suppl 2:15-21. Review.

PMID:
12442345

Supplemental Content

Support Center